Procedure is part of global clinical trial for technology developed by Israel’s CartiHeal, which hopes to bring relief to millions of sufferers of knee pain
Procedure is part of global clinical trial for technology developed by Israel’s CartiHeal, which hopes to bring relief to millions of sufferers of knee pain
BEDFORD, Mass.–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that regulatory authorities in Australia granted approval to MONOVISC®, Anika’s single injection viscosupplement for the treatment of pain associated with osteoarthritis of all synovial joints, including the hip and knee.
